Suppr超能文献

ISCHEMIA-CKD 试验中的肾脏移植名单状态和结果。

Kidney Transplant List Status and Outcomes in the ISCHEMIA-CKD Trial.

机构信息

Department of Medicine, Hennepin Healthcare, Minneapolis, Minnesota, USA; University of Minnesota, Minneapolis, Minnesota, USA.

Department of Medicine, Hennepin Healthcare, Minneapolis, Minnesota, USA; University of Minnesota, Minneapolis, Minnesota, USA.

出版信息

J Am Coll Cardiol. 2021 Jul 27;78(4):348-361. doi: 10.1016/j.jacc.2021.05.001. Epub 2021 May 11.

Abstract

BACKGROUND

Patients with chronic kidney disease (CKD) and coronary artery disease frequently undergo preemptive revascularization before kidney transplant listing.

OBJECTIVES

In this post hoc analysis from ISCHEMIA-CKD (International Study of Comparative Health Effectiveness of Medical and Invasive Approaches-Chronic Kidney Disease), we compared outcomes of patients not listed versus those listed according to management strategy.

METHODS

In the ISCHEMIA-CKD trial (n = 777), 194 patients (25%) with chronic coronary syndromes and at least moderate ischemia were listed for transplant. The primary (all-cause mortality or nonfatal myocardial infarction) and secondary (death, nonfatal myocardial infarction, hospitalization for unstable angina, heart failure, resuscitated cardiac arrest, or stroke) outcomes were analyzed using Cox multivariable modeling. Heterogeneity of randomized treatment effect between listed versus not listed groups was assessed.

RESULTS

Compared with those not listed, listed patients were younger (60 years vs 65 years), were less likely to be of Asian race (15% vs 29%), were more likely to be on dialysis (83% vs 44%), had fewer anginal symptoms, and were more likely to have coronary angiography and coronary revascularization irrespective of treatment assignment. Among patients assigned to an invasive strategy versus conservative strategy, the adjusted hazard ratios for the primary outcome were 0.91 (95% confidence interval [CI]: 0.54-1.54) and 1.03 (95% CI: 0.78-1.37) for those listed and not listed, respectively (p= 0.68). Adjusted hazard ratios for secondary outcomes were 0.89 (95% CI: 0.55-1.46) in listed and 1.17 (95% CI: 0.89-1.53) in those not listed (p = 0.35).

CONCLUSIONS

In ISCHEMIA-CKD, an invasive strategy in kidney transplant candidates did not improve outcomes compared with conservative management. These data do not support routine coronary angiography or revascularization in patients with advanced CKD and chronic coronary syndromes listed for transplant. (ISCHEMIA-Chronic Kidney Disease Trial [ISCHEMIA-CKD]; NCT01985360).

摘要

背景

患有慢性肾脏病(CKD)和冠状动脉疾病的患者经常在进行肾移植前进行预防性血运重建。

目的

在 ISCHEMIA-CKD(国际比较医疗和介入方法对慢性肾脏病的健康效果研究)的事后分析中,我们比较了根据管理策略进行列表和不列表的患者的结局。

方法

在 ISCHEMIA-CKD 试验(n=777)中,194 名(25%)患有慢性冠状动脉综合征和至少中度缺血的患者被列入移植名单。使用 Cox 多变量模型分析主要(全因死亡率或非致死性心肌梗死)和次要(死亡、非致死性心肌梗死、不稳定型心绞痛住院、心力衰竭、复苏性心脏骤停或中风)结局。评估随机治疗效果在列表与不列表组之间的异质性。

结果

与未列入名单的患者相比,列入名单的患者年龄较小(60 岁比 65 岁),亚洲种族的可能性较小(15%比 29%),更可能接受透析(83%比 44%),心绞痛症状较少,并且无论治疗分配如何,更有可能进行冠状动脉造影和冠状动脉血运重建。在被分配到侵袭性策略与保守策略的患者中,主要结局的调整后危险比分别为列入名单的 0.91(95%置信区间[CI]:0.54-1.54)和未列入名单的 1.03(95%CI:0.78-1.37)(p=0.68)。列入名单的次要结局的调整后危险比为 0.89(95%CI:0.55-1.46),未列入名单的为 1.17(95%CI:0.89-1.53)(p=0.35)。

结论

在 ISCHEMIA-CKD 中,与保守治疗相比,肾移植候选者的侵袭性策略并未改善结局。这些数据不支持在移植名单上患有晚期 CKD 和慢性冠状动脉综合征的患者进行常规冠状动脉造影或血运重建。(缺血性-慢性肾脏病试验[ISCHEMIA-CKD];NCT01985360)。

相似文献

1
Kidney Transplant List Status and Outcomes in the ISCHEMIA-CKD Trial.
J Am Coll Cardiol. 2021 Jul 27;78(4):348-361. doi: 10.1016/j.jacc.2021.05.001. Epub 2021 May 11.
4
Management of Coronary Disease in Patients with Advanced Kidney Disease.
N Engl J Med. 2020 Apr 23;382(17):1608-1618. doi: 10.1056/NEJMoa1915925. Epub 2020 Mar 30.
5
Left Main Revascularization With PCI or CABG in Patients With Chronic Kidney Disease: EXCEL Trial.
J Am Coll Cardiol. 2018 Aug 14;72(7):754-765. doi: 10.1016/j.jacc.2018.05.057.
7
Dialysis Initiation in Patients With Chronic Coronary Disease and Advanced Chronic Kidney Disease in ISCHEMIA-CKD.
J Am Heart Assoc. 2022 Mar 15;11(6):e022003. doi: 10.1161/JAHA.121.022003. Epub 2022 Mar 9.
8
Cardiovascular and Renal Implications of Myocardial Infarction in the ISCHEMIA-CKD Trial.
Circ Cardiovasc Interv. 2022 Aug;15(8):e012103. doi: 10.1161/CIRCINTERVENTIONS.122.012103. Epub 2022 Aug 16.
9
Cause-Specific Mortality in Patients With Advanced Chronic Kidney Disease in the ISCHEMIA-CKD Trial.
JACC Cardiovasc Interv. 2023 Jan 23;16(2):209-218. doi: 10.1016/j.jcin.2022.10.062.

引用本文的文献

5
The evaluation of kidney transplant candidates prior to waitlisting: a scoping review.
Clin Kidney J. 2024 Nov 22;18(1):sfae377. doi: 10.1093/ckj/sfae377. eCollection 2025 Jan.
6
Cardiovascular disease in waitlisted hemodialyzed patients.
Ren Fail. 2024 Dec;46(2):2440511. doi: 10.1080/0886022X.2024.2440511. Epub 2024 Dec 17.
7
Prognostic value of dobutamine stress echocardiography for the long-term outcomes in kidney transplant candidates.
Cardiovasc Diagn Ther. 2024 Oct 31;14(5):899-910. doi: 10.21037/cdt-24-174. Epub 2024 Sep 23.
8
Guideline for Perioperative Cardiovascular Evaluation of the Brazilian Society of Cardiology - 2024.
Arq Bras Cardiol. 2024 Oct 21;121(9):e20240590. doi: 10.36660/abc.20240590.
9
Pretransplant cardiac stress testing and transplant wait time in kidney transplantation candidates.
Open Heart. 2024 Sep 13;11(2):e002738. doi: 10.1136/openhrt-2024-002738.
10
Stent, balloon and hybrid in PCI: could the whole be greater than the sum of its parts?
Br J Cardiol. 2023 Nov 10;30(4):37. doi: 10.5837/bjc.2023.037. eCollection 2023.

本文引用的文献

1
Cardiac Imaging for Coronary Heart Disease Risk Stratification in Chronic Kidney Disease.
JACC Cardiovasc Imaging. 2021 Mar;14(3):669-682. doi: 10.1016/j.jcmg.2020.05.035. Epub 2020 Aug 19.
2
KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation.
Transplantation. 2020 Apr;104(4S1 Suppl 1):S11-S103. doi: 10.1097/TP.0000000000003136.
3
Management of Coronary Disease in Patients with Advanced Kidney Disease.
N Engl J Med. 2020 Apr 23;382(17):1608-1618. doi: 10.1056/NEJMoa1915925. Epub 2020 Mar 30.
4
Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review.
J Am Coll Cardiol. 2019 Oct 8;74(14):1823-1838. doi: 10.1016/j.jacc.2019.08.1017.
5
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes.
Eur Heart J. 2020 Jan 14;41(3):407-477. doi: 10.1093/eurheartj/ehz425.
7
Impact of Chronic Kidney Disease on Outcomes of Myocardial Revascularization in Patients With Diabetes.
J Am Coll Cardiol. 2019 Feb 5;73(4):400-411. doi: 10.1016/j.jacc.2018.11.044.
9
OPTN/SRTR 2016 Annual Data Report: Kidney.
Am J Transplant. 2018 Jan;18 Suppl 1(Suppl 1):18-113. doi: 10.1111/ajt.14557.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验